• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 15

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Essentials of Psychedelic Therapy & Integration

Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions

GLP-1 Drugs, Psilocybin Mushrooms, and the Case for Sublingual Psilocin

GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant...

2025’s Psychedelic Policy Surge: A State-by-State, Bill-by-Bill Analysis

The Psychedelic News Feed: September 2, 2024 – December 29, 2024

Psychedelic Drug Development Pipeline Updates (Q1’25)

Q1’25 Psychedelic Drug Development Pipeline: Bullseye Chart

How Do You Find the Right Facilitator? The Art of Matchmaking...

Pα+ Psychedelic Bulletin #186: As Trump Takes Office, Impact on Psychedelics...

Bifurcation Squared: Compass Lobbies for Narrow Rescheduling in Colorado, Virginia; Pushes...

Is the DEA Sabotaging Psychedelic Research? Inside the Push to Schedule...

Psychedelics in 2024: From Hype to Hard Realities

1...141516...294Page 15 of 294

EDITOR PICKS

From Huxley to Heffter: Mark Geyer Reflects on a Life in...

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Essentials of Psychedelic Therapy & Integration

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©